Table 1.
Main characteristics of the eligible studies.
| Study | Region | Case | Cancer type | Age | Cut-off value | Follow-up time (range) | Method | NOS score | SO |
|---|---|---|---|---|---|---|---|---|---|
| Au et al.33 | Canada | 511 | High-grade serous ovarian cancer | 65 | ROC | 34 m (1–150) | IHC | 8 | PFS |
| Chen et al.34 | Taiwan | 165 | Cervical cancer | 69 | 20% of the nuclei staining | 9.4 y (2.6–20) | IHC | 9 | OS |
| Gordziel et al.35 | Germany | 414 | Colorectal carcinoma | NR | scores 2–3 | 1–120 m | IHC | 6 | OS |
| Gujam et al.36 | Scotland | 384 | Breast cancer | >50 | NR | 148 m | IHC | 9 | DSS |
| Josahkian et al.37 | Canada | 65 | High-grade serous ovarian cancer | 55.5 | score 1.5–3 | 1–9 y | IHC | 8 | DFS and OS |
| Kaida et al.17 | Japan | 140 | Lung cancer | 73 | score 3 | 0–5 y | IHC | 6 | DFS and OS |
| Koti et al.38 | Canada | 183 | High-grade serous ovarian cancer | 61 | ROC | 1–150 m | IHC | 9 | OS and PFS |
| Laimer et al.39 | Austria | 33 | Squamous cell cancer of the oral cavity | 63.3 | 35% of the nuclei staining | 1–144 m | IHC | 9 | OS |
| Lin et al.40 | Taiwan | 97 | Pulmonary squamous cell carcinomas | 69 | positive staining in 5% | 1–250 m | IHC | 9 | DFS and OS |
| Pappa et al.41 | Greece | 49 | Oral squamous cell carcinoma | 59.2 | 35–70% staining | 1–7 y | IHC | 9 | OS |
| Simpson et al.42 | UK | 405 | Colorectal cancer | 72 | 10% of tumor cells staining | 42 m (1–116) | IHC | 7 | DSS |
| Sun et al.43 | China | 100 | Pancreatic cancer | 58.66 | a staining index of 6 | 20 m (1–84 m) | IHC | 8 | OS |
| Zhang et al.44 | China | 130 | Esophageal squamous cell carcinoma | 57 | staining scores 7 | 21.5 m (5–92 m) | IHC | 8 | OS |
| Zhou et al.45 | Sweden | 40 | Carcinoid tumors | NR | staining scores 2 | 1–200 m | IHC | 6 | OS |
| Zimmerman et al.46 | USA | 123 | Sarcoma | 61.3 | presence of expression | 1–120 m | IHC | 7 | DSS |
DFS, disease-free survival; DSS, disease-specific survival; IHC, immunohistochemistry; m, month; NOS, Newcastle-Ottawa-scale; NR, no report; OS, overall survival; PFS, progression-free survival; ROC, receiver operating characteristic; SO, survival outcome; y, year.